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Stroke Prevention Guidelines
To the Editor: Matchar and colleagues (1) cite the Stroke Prevention in Atrial Fibrillation (SPAF) study analyses (2, 3) to support the claim that "patients younger than 60 years who have a normal echocardiogram and no risk factors have an extremely low risk for stroke (1% per year)." Because the prevalence of atrial fibrillation is strongly related to advanced patient age, this scheme suggests that fewer than 5% of approximately 2 million Americans with atrial fibrillation would be at low risk. We reported that patients of any age with atrial fibrillation and without specific clinical or echocardiographic risk factors have a relatively low risk for ischemic stroke (3) . Such patients composed 26% of our study cohort and may represent an even larger portion of patients not enrolled in clinical trials (3) .
Warfarin is more effective than aspirin in preventing ischemic stroke in patients with atrial fibrillation as a group (relative risk reduction, 47%; 95% CI, 28% to 61%) (4). We contend, however, that anticoagulation therapy can be deferred for many patients with atrial fibrillation and a low intrinsic risk for stroke. These patients may benefit little from anticoagulation when absolute rates are considered ( Table 1) . The clinical risk stratifiers derived by analyses of patients in the SPAF study given placebo have been validated in other cohorts (4, 5) . Collaborative analysis of five primary prevention trials yielded similar, perhaps more generalizable, stratification variables. The ongoing SPAF III study is attempting to define additional subgroups of patients with atrial fibrillation who can be maintained at low risk with aspirin and for whom the need for lifelong anticoagulation may be reasonably postponed. In response: Recent clinical trials, including SPAF, have shown that anticoagulation with warfarin sodium can reduce the risk for stroke in patients with atrial fibrillation. As stated in our review, this relative risk reduction may not be worth the risks attendant to anticoagulation in patients in whom the absolute risk is small (1) .
Robert
The crucial question is, who has a small absolute risk? The answer has been, and continues to be, a moving target. Indeed, since the submission of our manuscript, a pooled analysis by the Atrial Fibrillation Investigators has shown that persons with lone atrial fibrillation had a relatively low risk for stroke at any age (2) . One caveat is that these data were derived not from a population-based survey but rather from the experience of vol- 
Omeprazole Therapy in Resistant Reflux Disease
To the Editor: In the recently published article on long-term omeprazole treatment (1), the authors attempted to explain the greater than tenfold elevation of plasma gastrin levels in 10 of 91 patients (11%) enrolled in the long-term omeprazole treatment study. We suggest that most, if not all, of these patients could be genetically determined to lack activity of the major enzyme responsible for metabolizing omeprazole, CYP IIC19. After 1 week of oral omeprazole (20 mg/d) given to both rapid and poor metabolizers, poor metabolizers showed a 2.9-fold greater halflife, a 4.8-fold greater maximum plasma concentration, and an 11.7-fold greater plasma area under the curve of omeprazole than did rapid metabolizers (2) . Poor metabolizer frequency varies ethnically, with about 5% of whites (2) and as many as 22% of Asians (3) expressing the poor metabolizer phenotype. Rapid and poor metabolizers of omeprazole can be identified with a mephenytoin-phenotyping technique (4).
Omeprazole-induced hypergastrinemia and decreased vitamin B 12 absorption (5) are significant causes of concern for patients receiving long-term omeprazole therapy. Long-term omeprazole therapy would probably put persons with poor metabolism of omeprazole at increased risk for significant vitamin B 12 malabsorption, potentially leading to vitamin B 12 deficiency.
We propose that poor metabolizers of omeprazole and Smephenytoin are those at greatest risk for these and other longterm toxicities associated with omeprazole. Because poor metabolizers of omeprazole cannot readily be identified, we recommend that 1) long-term therapy with omeprazole be limited to the few persons with chronic erosive esophagitis and the Zollinger-Ellison syndrome who cannot be treated with other available therapies; 2) all patients receiving long-term omeprazole therapy have annual gastroscopy and B 12 measurements; 3) gastrin levels be measured after 3 months of omeprazole therapy; 4) persons with abnormally high gastrin levels or other omeprazole-related toxicities be phenotyped with mephenytoin; and 5) poor metabolizers of mephenytoin receive a markedly reduced dose of omeprazole (for example, 20 mg once or twice weekly). To the Editor: We read with interest the article by KlinkenbergKnol and coworkers (1) on omeprazole safety and the accompanying editorial by Freston (2) . Although the report by Klinkenberg-Knol and colleagues (1) offered a well-balanced description of gastrin values and micronodular neuroendocrine cell hyperplasia in the oxyntic mucosa of many patients receiving omeprazole maintenance treatment, the editorial (2) tended to underestimate the risks for hypergastrinemia. Thus, it was not considered that the maximal functional and trophic effects of gastrin in the rat and in humans on the enterochromaffin-like (ECL) cell are reached at a concentration of less than 500 pM (3). Therefore, greatly elevated gastrin values in patients with pernicious anemia are irrelevant. It is speculative to propose that the ECL-cell hyperplasia in patients with omeprazole-induced hypergastrinemia is the result of gastritis (4) because it is well known that hypergastrinemia itself is sufficient to provoke such changes in animals. Klinkenberg-Knol and colleagues reported that many patients retained food in the stomach, which could have contributed to the hypergastrinemia. This food retention could, however, be secondary to the omeprazole treatment (5). Also, Larsson and colleagues from the Hassle Group have reported such a finding at high omeprazole doses in the rat.
Considering that carcinogenesis is often a process that requires decades, and that neuroendocrine cells (including ECL cells) (3) may give rise to malignant gastric tumors, it seems biased to conclude that there is a "diminishing concern about omeprazoleinduced hypergastrinemia" (2) . It should be realized that ECL cell-derived tumors developed in rats after lifelong hypergastrinemia and that an observation period of a few years is far too brief to exclude serious long-term consequences in humans. The micronodular neuroendocrine cell hyperplasia reported by Klinkenberg-Knol and colleagues resembles the changes occurring in rats before the development of carcinoid tumors. Therefore, iatrogenic hypergastrinemia should be avoided, particularly in younger persons.
Helge L. Waldum, MD Eiliv Brenna, MD University Hospital N-7006 Trondheim Norway
In response: Wright and Sarich's recommendation to reserve long-term omeprazole therapy for patients with severe, erosive esophageal disease who cannot be managed with other available therapies would be reasonable if the alternative long-term therapies for less severe disease were equally efficacious, safe, and cost-effective. This recommendation, however, would exclude promotility drugs (because of their reduced efficacy and unknown long-term safety) and histamine-2-receptor antagonists in standard doses (because of their reduced efficacy) and in high doses (because of probable reduced efficacy, unknown long-term safety, and increased cost compared with omeprazole).
The combination of serum gastrin determinations every 3 months and yearly gastroscopies should not be recommended without evidence that the associated costs will be offset by improved safety. Gastrin levels may vary sixfold in persons tested every 3 or 4 months during long-term omeprazole therapy, and yearly testing is as likely as thrice-yearly testing to identify patients with gastrin levels greater than 400 pg/mL (1). Graham's extraordinary recommendation that gastroscopies be done annually during omeprazole therapy was based on his observation of gastric mucosal nodularity in some patients (2) . The nodules have since been shown to be mucosal cysts of no known clinical relevance (3) .
Regardless of their rate of omeprazole metabolism, patients with high gastrin levels should have a trial of low-dose omeprazole or histamine-2 blockers because they may not need a high degree of gastric acid inhibition. Meanwhile, the effects of slow omeprazole metabolism on acid secretion, gastrin levels, and vitamin B 12 absorption should be measured. Such pharmacodynamics data will be more useful than pharmacokinetics data in the creation of sound clinical recommendations.
Waldum and Brenna's observation that the maximum trophic effects of gastrin are reached at concentrations of less than 500 pM underscores the importance of an additional factor operating in patients with pernicious anemia and the Zollinger-Ellison syndrome in whom gastric carcinoid tumors develop; that is, hypergastrinemia appears to be necessary but not necessary and sufficient. The additional factor, possibly related to the multiple endocrine neoplasia type I gene in patients with the ZollingerEllison syndrome and to chronic inflammation in patients with pernicious anemia appears to trigger a transformation from ECLcell hyperplasia to dysplasia and neoplasia.
To deny that safety concerns about omeprazole are diminishing is to ignore facts. Since the discovery of omeprazole-induced gastric carcinoid tumors in rats nearly a decade ago, regulatory agencies throughout the world have approved the use of omeprazole, including its long-term use in several countries. These developments reflect an increased understanding of the mechanism of carcinoid formation, the absence of omeprazole-induced ECL-cell dysplasia or carcinoid tumors in long-term clinical trials, and the absence of carcinoid tumors in surveillance studies among the estimated 60 million patients who have been treated with omeprazole. It is also reassuring that gastric carcinoids are not known to occur years after gastric vagotomy, which causes gastrin elevations greater than those resulting from omeprazole therapy (4).
Safety concerns persist, of course, and continued surveillance is necessary. Meanwhile, clinicians can use omeprazole to treat patients with recurrent esophagitis and can know that they are practicing within the experience of excellent long-term safety trials such as those of Lamberts and colleagues (5) and Klinkenberg-Knol and colleagues.
James W. Freston, MD, PhD University of Connecticut Health Center Farmington, CT 06030
In response: Drs. Waldum and Brenna express their concerns regarding omeprazole-induced hypergastrinemia. We have recommended continued follow-up of patients receiving long-term therapy with proton-pump inhibitors, particularly patients with high serum gastrin levels that showed enhanced progression toward atrophic gastritis. The significance of this finding remains unclear and requires further study. This follow-up strategy also applies to the risk for progression from hyperplasia to dysplasia of ECL cells.
Concerning the potential cause of food retention in patients with high gastrin levels, we have postulated that omeprazole might be responsible for the food retention caused by the decreased emptying rate of solid food in healthy volunteers (1) (2) (3) . Another explanation might be decreased antral motility (4) and delayed gastric emptying caused by elevated serum gastrin levels. Vagal nerve damage might also be among the factors causing delayed gastric emptying in some of our patients.
Drs. Wright and Sarich suggest that the severe hypergastrinemia observed in 10 of 91 patients receiving long-term omeprazole therapy might be caused by a difference in metabolism of the drug. If their hypothesis is correct, a lower dose of omeprazole should be needed in these patients to achieve remission. However, we did not observe a decreased need for the drug. In contrast, these patients experienced frequent recurrences during maintenance treatment with omeprazole (20 mg/d or 40 mg/d). In our opinion, the main cause of this severe hypergastrinemia is delayed gastric emptying.
Profound acid inhibition may interfere with the absorption of certain nutrients such as iron and cobalamin (5). However, although the resorption of protein-bound cobalamin was found to decrease during omeprazole treatment, no changes in serum cobalamin levels were detected during continuous maintenance therapy that lasted as long as 4 years (5). Similarly, no changes in several other metabolic measurements were found during long-term treatment.
We agree that conscientious behavior by physicians in prescribing proton-pump inhibitors, particularly in young patients, is still required. 
Omeprazole, Serum Gastrin, and Gastric Acid Suppression
To the Editor: It is well known that the decrease in gastric activity caused by omeprazole results in increased serum gastrin levels. We asked whether a precise relation exists between fasting serum gastrin levels and gastric acid suppression in patients receiving omeprazole. If such a relation exists, physicians could obtain fasting serum gastrin levels from their patients receiving omeprazole as a simple measure of the degree of gastric acid suppression. We used ambulatory intragastric pH monitoring to assess gastric acid suppression in 45 patients with gastroesophageal reflux who were receiving different doses of omeprazole. The pH probe was placed with the antimony electrode in the To determine whether this relation was affected by the omeprazole dose, we also compared the fasting serum gastrin level with the total percentage of time the intragastric pH remained less than 4.0 on individual doses. A poor correlation was consistently found at all dose levels.
We conclude that serum gastrin levels do not reliably predict the degree of gastric acid suppression in patients receiving omeprazole. 
R. Matthew Gideon

